Inventor
JURE-KUNKEL MARIA
US29 patents
⚠️ This page may combine multiple inventors who share the name “JURE-KUNKEL MARIA”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
BRISTOL MYERS SQUIBB CO
23 patentsUS10072082B2Sep 11, 2018
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
BRISTOL MYERS SQUIBB CO58 citations99
US10604575B2Mar 31, 2020
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
BRISTOL MYERS SQUIBB CO26 citations98
US10584170B2Mar 10, 2020
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
BRISTOL MYERS SQUIBB CO23 citations98
US10577423B2Mar 3, 2020
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
BRISTOL MYERS SQUIBB CO23 citations98
US10323092B2Jun 18, 2019
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
BRISTOL MYERS SQUIBB CO30 citations98
US10323093B2Jun 18, 2019
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
BRISTOL MYERS SQUIBB CO29 citations98
US10316090B2Jun 11, 2019
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
BRISTOL MYERS SQUIBB CO29 citations98
US10316091B2Jun 11, 2019
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
BRISTOL MYERS SQUIBB CO30 citations98
US10308714B2Jun 4, 2019
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
BRISTOL MYERS SQUIBB CO30 citations98
US10266594B1Apr 23, 2019
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
BRISTOL MYERS SQUIBB CO29 citations98
US10266595B2Apr 23, 2019
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
BRISTOL MYERS SQUIBB CO28 citations98
US10266596B1Apr 23, 2019
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
BRISTOL MYERS SQUIBB CO29 citations98
US10138299B2Nov 27, 2018
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
BRISTOL MYERS SQUIBB CO39 citations98
US9856320B2Jan 2, 2018
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
BRISTOL MYERS SQUIBB CO94 citations98
US7288638B2Oct 30, 2007
Fully human antibodies against human 4-1BB
BRISTOL MYERS SQUIBB CO245 citations98
US9212224B2Dec 15, 2015
Antibodies that bind PD-L1 and uses thereof
BRISTOL MYERS SQUIBB CO135 citations97
US7659384B2Feb 9, 2010
Polynucleotides encoding fully human antibodies against human 4-1BB
BRISTOL MYERS SQUIBB CO38 citations95
US10100129B2Oct 16, 2018
Antibodies against CD73 and uses thereof
BRISTOL MYERS SQUIBB CO24 citations93
US9320811B2Apr 26, 2016
Combination of anti-CTLA4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
BRISTOL MYERS SQUIBB CO17 citations92
US9382328B2Jul 5, 2016
Fully human antibodies against human 4-1BB
BRISTOL MYERS SQUIBB CO15 citations91
US12590154B2Mar 31, 2026
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
BRISTOL MYERS SQUIBB CO0 citations73
US11344639B2May 31, 2022
PET imaging with PD-L1 binding polypeptides
BRISTOL MYERS SQUIBB CO4 citations71
US11173219B2Nov 16, 2021
PD-L1 binding polypeptides for imaging
BRISTOL MYERS SQUIBB CO4 citations71
JURE-KUNKEL MARIA
6 patentsUS8119129B2Feb 21, 2012
Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases
JURE-KUNKEL MARIA165 citations98
US8475790B2Jul 2, 2013
Combination of CD137 antibody and CTLA-4 antibody for the treatment of proliferative diseases
JURE-KUNKEL MARIA57 citations97
US8716452B2May 6, 2014
Fully human antibodies against human 4-1BB
JURE-KUNKEL MARIA41 citations96
US8137667B2Mar 20, 2012
Fully human antibodies against human 4-1BB
JURE-KUNKEL MARIA39 citations96
US8685394B2Apr 1, 2014
Combination of anti-CTLA4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
JURE-KUNKEL MARIA28 citations92
US8449886B2May 28, 2013
Combination of anti-CTLA4 antibody with tubulin modulating agents for the treatment of proliferative diseases
JURE-KUNKEL MARIA11 citations84